Design, optimization and validation of compounds against cancer-Initiating cells.

Forschungsstelle

INNOSUISSE

Projektnummer

12985.1;6 PFLS-LS

Projekttitel

Design, optimization and validation of compounds against cancer-Initiating cells.

Projekttitel Englisch

Design, optimization and validation of compounds against cancer-Initiating cells.

Texte zu diesem Projekt

	Deutsch	Französisch	Italienisch	Englisch
Kurzbeschreibung		-	-
Abstract		-	-

Kategorie	Text
Kurzbeschreibung (Deutsch)	Design, optimization and validation of compounds against cancer-Initiating cells.
Kurzbeschreibung (Englisch)	Design, optimization and validation of compounds against cancer-Initiating cells.
Abstract (Deutsch)	This CTI project aims at identifying a preclinical candidate and generate a selection of back-up compounds to treat brain cancer, in order to accelerate and improve the development programs of Stemergie Biotechnology SA. The combination of the unique technology expertise of Stemergie in cancer-initiating cells with the medicinal chemistry technologies and know-how of the Carreira Group at the ETH Zurich shall enable the development of novel drug candidates to treat brain cancer patients.
Abstract (Englisch)	This CTI project aims at identifying a preclinical candidate and generate a selection of back-up compounds to treat brain cancer, in order to accelerate and improve the development programs of Stemergie Biotechnology SA. The combination of the unique technology expertise of Stemergie in cancer-initiating cells with the medicinal chemistry technologies and know-how of the Carreira Group at the ETH Zurich shall enable the development of novel drug candidates to treat brain cancer patients.